Published 3 hours ago • loading... • Updated 20 minutes ago
Sellas’ Cancer Vaccine Extends Survival in Blood Cancer Trial
The vaccine cut the risk of death by 41% and extended median overall survival to 24.0 months, the company said.
On Tuesday, SELLAS Life Sciences Group, Inc. announced positive topline results from the pivotal Phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia .
The REGAL trial evaluated GPS as maintenance monotherapy in 126 patients with AML who achieved a second or later complete remission and were ineligible for allogeneic stem cell transplantation.
GPS demonstrated a 41% reduction in the risk of death, with median overall survival of 24.0 months versus 14.7 months for patients receiving best available treatment.
SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy, advancing preparations for a Biologics License Application submission in the first half of 2027.
Calling the data a "defining milestone," Angelos Stergiou, President and Chief Executive Officer of SELLAS, said the trial validates the company's WT1-targeted immunotherapeutic technology.